Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia
Authors
Keywords
-
Journal
CURRENT OPINION IN ONCOLOGY
Volume 25, Issue 6, Pages 701-706
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2013-10-07
DOI
10.1097/cco.0000000000000009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
- (2012) N. Gokbuget et al. BLOOD
- Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia
- (2012) Hagop Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Chemoimmunotherapy in acute lymphoblastic leukemia
- (2011) Dieter Hoelzer et al. BLOOD REVIEWS
- The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies
- (2011) Y-C Linn et al. BONE MARROW TRANSPLANTATION
- The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells
- (2011) Eva Rettinger et al. CYTOTHERAPY
- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
- (2011) Sara Raponi et al. LEUKEMIA & LYMPHOMA
- Adult acute lymphoblastic leukemia
- (2010) Stefan Faderl et al. CANCER
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
- (2010) Deborah A. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
- (2010) R Handgretinger et al. LEUKEMIA
- Prognostic implications of anemia in older adults
- (2009) K. V. Patel et al. HAEMATOLOGICA
- A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report
- (2009) Anne L. Angiolillo et al. PEDIATRIC BLOOD & CANCER
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More